UK Parliament / Open data

Animal Testing

Proceeding contribution from Grahame Morris (Labour) in the House of Commons on Monday, 25 October 2021. It occurred during e-petition debate on Animal Testing.

It is a pleasure to serve under your chairmanship, Ms Elliot. I congratulate the hon. Member for Linlithgow and East Falkirk (Martyn Day) on opening the debate and on the forceful and cogent argument he put forward to make the case for the petitioners. I also thank good and hon. Members across the House who have spoken so forcefully on this issue. I support petitions 581641 and 590216, signed by more than 320,000 petitioners, quite a number of whom were from my constituency.

I wish to declare an interest as chair of the all-party parliamentary group on human-relevant science. It would be remiss of me not to take the opportunity to pay tribute briefly to the late vice-chair of the group, Sir David Amess. He was an unwavering voice for animals in laboratories and a champion for human-relevant science. He will be remembered as a tireless and principled campaigner for animal welfare. I hope that Members from the Government side, who are absent from tonight’s debate, will step up and take on Sir David’s mantle.

The APPG on human-relevant science is a discussion forum in which politicians, the human-relevant life sciences sector, the third sector, scientists and stakeholders can promote new-approach methodologies that provide unique insights into human biology, transform our ability to understand human disease, and develop new and effective medicines more quickly, without the use of animals.

I certainly take on board the point made earlier that the stats seem to show a slight reduction in the number of animals used in testing in 2020. However, that might be a consequence of the pandemic. In the 10 years up to 2019 the average annual decrease in animal testing was only about 1% a year. On that trajectory, animal testing looks like it is set to continue for another 90 years.

The case for transition to human-relevant science is absolutely compelling. A growing range of cutting-edge techniques provide results that are directly relevant to people and that can replace, or at the very least significantly reduce, the use of animals. Such new-approach method-ologies include the use of human cells, tissues, tissue cultures, artificial intelligence and organ-on-a-chip technology.

Significant differences in the human race’s genetic make-up mean that data from animal experiments cannot be reliably translated into humans. In fact, the current

reliance on animal experiments may well be holding back the progress that many patients so urgently need. More than 92% of drugs that show promise in animal tests fail to reach the clinic and do not benefit patients, mostly for reasons of poor efficacy and safety that were not predicted by animal testing. In disease research, the picture is similar. Decades of efforts towards understanding neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, and towards finding effective therapies for them, have been huge failures due to the majority of animal experiments lacking human relevance.

The APPG on human-relevant science has held several meetings by Zoom over the past year, examining two main areas: funding barriers and regulatory barriers. As it stands, the funding made available for research via the National Centre for the Replacement, Refinement and Reduction of Animals in Research—the NC3Rs that the hon. Member for Linlithgow and East Falkirk referred to—is not sufficient to support the transition to human-relevant research. Indeed, the NC3Rs’s annual budget amounts to only around £10 million. By comparison, the Association of Medical Research Charities estimates that the Medical Research Council and the National Institute for Health Research provided a combined total of £1.8 billion in funding for UK medical research in 2019, while medical research charities provided £1.9 billion.

The economic potential of animal-free methods is huge. By providing results that are directly relevant to people, new-approach methodologies can accelerate the development of effective treatments that will transform patients’ lives and reduce the economic cost of ill health. I hope the Minister will respond to the important point raised earlier that over 450 skin sensation tests were carried out on mice in 2020, even though validated non-animal tests were and are available. In 2020, not a single application for licences to conduct experiments on animals were refused permission.

There is major public support for replacing animal testing with human-relevant techniques, and the petitions that formed the basis for today’s debate attest to that. A YouGov poll also shows enormous public support. The Government must take decisive and ambitious action to phase out animal experiments and phase in the use of cutting-edge, human-relevant techniques. Modernising medical research in this way will deliver major benefits for people, animals and the UK economy.

6.34 pm

About this proceeding contribution

Reference

702 cc30-1WH 

Session

2021-22

Chamber / Committee

Westminster Hall
Back to top